|1.||London, Cheryl A: 6 articles (01/2013 - 07/2003)|
|2.||Kisseberth, William C: 2 articles (01/2013 - 01/2012)|
|3.||Yancey, M F: 2 articles (04/2010 - 04/2010)|
|4.||Merritt, D A: 2 articles (04/2010 - 04/2010)|
|5.||Chien, May B: 2 articles (04/2006 - 07/2003)|
|6.||Cherrington, Julie M: 2 articles (11/2003 - 07/2003)|
|7.||Williams, L E: 1 article (07/2015)|
|8.||Burton, J H: 1 article (07/2015)|
|9.||Vail, D M: 1 article (07/2015)|
|10.||Axiak-Bechtel, S M: 1 article (07/2015)|
07/01/2003 - "This was a Phase I trial in which successive cohorts of dogs with spontaneous tumors that had failed standard treatment regimens received escalating doses of SU11654 as oral therapy. "
01/01/2014 - "Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor."
01/01/2013 - "Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose."
05/01/2012 - "Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer."
04/01/2010 - "These pharmacokinetic parameters support every-other-day administration of toceranib phosphate at an initial dose of 3.25 mg/kg for the treatment of mast cell tumors in dogs."
04/01/2006 - "Furthermore, SU11654 did not induce cell-cycle arrest or apoptosis of histiocytic sarcoma lines, even at supratherapeutic doses. "
04/01/2006 - "The ability of the multi-targeted split-kinase inhibitor SU11654 to block proliferation and induce apoptosis of histiocytic sarcoma cell lines was also evaluated. "
|3.||Thyroid Neoplasms (Thyroid Cancer)
|2.||tyrosine receptor (receptor, tyrosine)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)